Skip to main content
Publications
Aparicio J, Virgili Manrique AC, Capdevila J, Munoz Boza F, Galvan P, Richart P, Oliveres H, Paez D, Hernando J, Serrano S, Vera R, Hernandez‑Yague X, Gallego RA, Riesco‑Martinez MC, Garcia de Albeniz Martinez X, Maurel J. Randomized phase II trial of FOLFIRI‑panitumumab compared with FOLFIRI alone in patients with RAS wild‑type circulating tumor DNA metastatic colorectal cancer beyond progression to first‑line FOLFOX‑panitumumab: the BEYOND study (GEMCAD 17‑01). Clin Trans Oncol. 2022 Nov;24(11):2155-65. doi: 10.1007/s12094-022-02868-x
Paquette M, Franca LR, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, Rothman KJ, Zint K, Halperin JL, Olshansky B, Huisman MV, Lip GYH, Nieuwlaat R. Dabigatran persistence and outcomes following discontinuation in atrial fibrillation patients from the GLORIA-AF registry. Am J Cardiol. 2020 Feb 1;125(3):383-91. doi: 10.1016/j.amjcard.2019.10.047
Ribera A, Ferreira-Gonzalez I, Marsal JR, Cascant P, Permanyer-Miralda G, Abdul-Jawad O, Inigo-Garcia LA, Guarinos-Oltra J, Cequier A, Goicolea-Guemez L, Garcia-Del-Blanco B, Marti G, Garcia-Dorado D. Prognostic value of an abnormal ankle-brachial index in patients receiving drug-eluting stents. Am J Cardiol. 2011 Nov 1;108(9):1225-31. doi: 10.1016/j.amjcard.2011.06.036